Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Oncogene ; 38(11): 1815-1831, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30368528

RESUMEN

Vasculogenic mimicry (VM) refers to the fluid-conducting channels formed by aggressive tumor cells rather than endothelial cells (EC) with elevated expression of genes associated with vascularization. VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy. However, the molecular basis underlying VM formation remains unclear. Here we report that the insulin-like growth factor-binding protein 2 (IGFBP2) acts as a potent factor to enhance VM formation in glioma. Evidence showed that elevated IGFBP2 expression was positively related with VM formation in patients with glioma. Enforced expression of IGFBP2 increased network formation of glioma cells in vitro by activating CD144 and MMP2 (Matrix Metalloproteinase 2). U251 cells with stable knockdown of IGFBP2 led to decreased VM formation and tumor progression in orthotopic mouse model. Mechanistically, IGFBP2 interacts with integrin α5 and ß1 subunits and augments CD144 expression in a FAK/ERK pathway-dependent manner. Luciferase reporter and ChIP assay suggested that IGFBP2 activated the transcription factor SP1, which could bind to CD144 promoter. Thus, IGFBP2 acts as a stimulator of VM formation in glioma cells via enhancing CD144 and MMP2 expression.


Asunto(s)
Neoplasias Encefálicas , Glioma , Receptores de Hialuranos/genética , Proteína 2 de Unión a Factor de Crecimiento Similar a la Insulina/fisiología , Metaloproteinasa 2 de la Matriz/genética , Neovascularización Patológica/genética , Animales , Neoplasias Encefálicas/irrigación sanguínea , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Línea Celular Tumoral , Movimiento Celular/genética , Regulación Neoplásica de la Expresión Génica , Glioma/irrigación sanguínea , Glioma/genética , Glioma/patología , Humanos , Receptores de Hialuranos/metabolismo , Proteína 2 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Ratones Transgénicos , Neovascularización Patológica/patología , Transducción de Señal/genética
2.
Genet Mol Res ; 14(4): 12074-84, 2015 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-26505354

RESUMEN

The association between the CCDC26 rs4295627 single nucleotide polymorphism (SNP) and the glioma risk has been studied previously, but these studies have yielded conflicting results. The aim of the present study is to analyze this association more vigorously, by means of a meta-analysis. A comprehensive literature search was performed in databases PubMed and EMBASE. Six articles including 12 case-control studies in English with 11,368 controls and 5891 cases were eligible for the meta-analysis. We conducted subgroup analyses by the source of controls, ethnicity, and country. Our meta-analysis revealed that the rs4295627 SNP was associated with the glioma risk in a heterozygote model (TG versus TT: odds ratio = 1.35, 95% confidence interval = 1.26-1.45, P = 0.066). Moreover, our results suggested that the rs4295627 SNP was associated with a notably increased risk of glioma among Caucasians except for Swedes in 4 models (the homozygote model, recessive model, dominant model, and additive model). Nonetheless, in Sweden and China, the results showed no associations. No evidence of the publication bias was uncovered. Thus, our meta-analysis suggests that the rs4295627 SNP is associated with an increased risk of glioma. Additional studies are needed to derive more precise conclusion.


Asunto(s)
Neoplasias Encefálicas/genética , Glioma/genética , Péptidos y Proteínas de Señalización Intracelular/genética , Polimorfismo de Nucleótido Simple , Neoplasias Encefálicas/etnología , Estudios de Casos y Controles , China , Glioma/etnología , Humanos , ARN Largo no Codificante , Suecia
3.
Technol Cancer Res Treat ; 10(1): 95-100, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21214292

RESUMEN

The immunological consequences of cryoablation for gliomas are largely unknown. cryoablation is an attractive therapeutic option for tumors due to its minimally invasive nature. cryoablation is also potentially immunogenic. With an aim to explore changes in cellular immunity following argon-helium cryosurgery, we established Wistar rat models bearing subcutaneous C6 glioma and divided the rats into the normal control (30 rats), sham-operated (33 rats), surgical resection (30 rats), and cryosurgery (33 rats) groups with corresponding treatments. The tumor cell morphology was observed, and changes in the T lymphocyte subset and NK lymphocyte subset and the ratio of Th1/Th2 were assessed with flow cytometry following the cryosurgery. The results showed that subcutaneous tumor implantation was successful in all cases and this was confirmed histologically. Compared with surgical resection that caused significant reduction in CD3(+), CD4(+), CD14(+), CD16+56 cell percentages, cryosurgery resulted in significantly increased percentages of CD3(+), CD4(+), CD14(+), CD16+56 cells (P < 0.05) with a increase of the Th1/Th2 ratio 7 days after the operation. These results demonstrate that in addition to tumor cell destruction, cryosurgery also results in enhanced cellular immunity, suggesting the great potential of argon-helium cryosurgery in clinical management of gliomas.


Asunto(s)
Criocirugía , Glioma/inmunología , Glioma/cirugía , Inmunidad Celular , Animales , Citocinas/metabolismo , Modelos Animales de Enfermedad , Citometría de Flujo , Células Asesinas Naturales/inmunología , Ratas , Ratas Wistar , Linfocitos T/inmunología , Balance Th1 - Th2
4.
Br J Cancer ; 82(10): 1694-701, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10817506

RESUMEN

Vascular endothelial growth factor (VEGF) is one of the most potent factors for stimulating angiogenesis, an essential process required for expansion of primary tumour and dissemination of malignant cells. To investigate the possible role of VEGF in facilitating metastasis of prostate cancer via stimulating angiogenesis, we have used Northern and slot blotting, reverse transcription polymerase chain reaction, nucleotide sequence analysis and enzyme-linked immunosorbent assay to compare the VEGF expression in series of human and rat cell lines with either benign or malignant characteristics. We have also employed the chick chorioallantoic membrane (CAM) assay to measure the angiogenic activity of the VEGF derived from both benign and malignant cells. The level of VEGF mRNA expressed in the seven malignant human and rat cell lines is 3.5- to 10-fold higher than that expressed in the benign cell lines. The three metastatic variants, generated by transfection of a benign cell line with DNA extracted from prostate carcinoma cells, expressed 2.5 to 5 times more VEGF mRNA than their parental benign cells. While VEGF 121 and 165 were predominantly expressed by both the benign and malignant cells, the transcript representing VEGF 189 isoform was only detected in the malignant cells. At protein level, three human malignant cell lines produced more VEGF (2.7-7.9 ng ml(-1)) than the benign cell line (1.3 ng ml(-1)). CAM assay detected a VEGF-dependent angiogenic activity in the medium from malignant cells, but only a relatively weak VEGF-independent activity in the medium from benign cells. These results demonstrated that malignant cells did over-express VEGF and only the VEGF derived from malignant cells was angiogenically active. Thus, we suggest that the VEGF produced by malignant cells might play an important role in facilitating metastasis of prostatic cancer.


Asunto(s)
Factores de Crecimiento Endotelial/fisiología , Linfocinas/fisiología , Proteínas de Neoplasias/metabolismo , Próstata/metabolismo , Neoplasias de la Próstata/metabolismo , Alantoides/irrigación sanguínea , Animales , Embrión de Pollo , Corion/irrigación sanguínea , Factores de Crecimiento Endotelial/metabolismo , Humanos , Linfocinas/metabolismo , Masculino , Metástasis de la Neoplasia , Neovascularización Fisiológica , Neoplasias de la Próstata/irrigación sanguínea , Neoplasias de la Próstata/patología , ARN Mensajero/metabolismo , Ratas , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular
5.
Biochem Biophys Res Commun ; 171(3): 963-71, 1990 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-1699532

RESUMEN

Recombinant human acidic fibroblast growth factor has been produced in E. coli cells at a level of at least 50 mg/l culture. The recombinant and natural acidic fibroblast growth factors are almost identical to one another when tested on rat mammary fibroblasts for their ability to stimulate DNA synthesis, to bind to the high-affinity surface receptors of the cells and to inhibit DNA synthesis when present in the culture medium at high concentrations. The recombinant acidic fibroblast growth factor binds to two cell-surface polypeptides of molecular masses 160 kDa and 140 kDa, which are the same size as the receptors for basic fibroblast growth factor, and it binds preferentially to the smaller polypeptide.


Asunto(s)
Replicación del ADN/efectos de los fármacos , Factor 1 de Crecimiento de Fibroblastos/aislamiento & purificación , Glándulas Mamarias Animales/citología , Animales , Línea Celular , Escherichia coli/genética , Factor 1 de Crecimiento de Fibroblastos/genética , Factor 1 de Crecimiento de Fibroblastos/metabolismo , Factor 1 de Crecimiento de Fibroblastos/farmacología , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Genes Sintéticos , Peso Molecular , Mapeo Peptídico , Plásmidos , Ratas , Receptores de Superficie Celular/metabolismo , Receptores de Factores de Crecimiento de Fibroblastos , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacología , Timidina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA